HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment

Brazilian Journal of Infectious Diseases

Volumn 9, Issue 4, 2005, Pages 324-329

  Tupinambás, Unaí ^a   Aleixo, Agdemir ^c   Greco, Dirceu ^b,c  

^a Belo Horizonte Secretary of Health   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Health State Office of Minas Gerais   (Brazil)

Author keywords

HIV 1; Nelfinavir; Protease inhibitors

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; DIDANOSINE; LEUCINE; LYSINE; METHIONINE; NELFINAVIR; NUCLEOSIDE; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VALINE;

ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CROSS RESISTANCE; DATA ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; TREATMENT FAILURE; VIRUS EXAMINATION; VIRUS STRAIN; WILD TYPE;

EID: 31344466766     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702005000400009     Document Type: Article

References (19)

1. Perelson A.S., Essunger P., Cao Y., et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91.
2. Gulick R.M., Mellors J.W., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Eng J Med 1997; 337:734-9.
3. Marins J.R., Jamal L.F., Chen S.Y., et al. Dramatic improvement in survival among adult Brazilian Aids patients. AIDS 2003;17:1675-82.
4. Palella F.J., Kathellen M.D., Anne C.M., et al. Decline Morbidity among patients with Advanced Human Immunodeficiency Virus Infection. N Engl L Med 1998;338:853-60.
5. Shafer R.W., Winters M.A., Palmer S., et al. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998;128:906-11.
6. Eastman P.S., Mittler J., Kelso R., et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma vital RNA levels subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998;72:5154-64.
7. Haubrich R.H., Little S.J., Currier J.S., et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-107.
8. Deeks S., Hecht F., Swanson M., et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS Clinic: Response to both initial and salvage therapy. AIDS 1999;13F35-F43.
9. Kemper C.A., Witt M.D., Keiser P.H., et al. Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15:609-15.
10. Rodrigues-Rosado R., Briones C., Soriano V. Introduction of drug resistance testing in clinical practice. AIDS 1999;13:1007-14.
11. Harrigan R., Coté H. Clinical utility of testing HIV for drug resistance. Clin Infect Dis 2000;30(Suppl. 2):117-22.
12. Patick A.K., Duran M., Cao Y., et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998;42(10):2637-44.
13. Clotet B., Ruiz L., Matinez-Picado J., et al. Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HARRT: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts. HIV Clin Trials 2002;3:316-23.
14. Tebas P., Patick A., Kane E., et al. Virologic response to a ritonavir-saquinavir-containing regimen in patient who had previously failed nelfinavir. AIDS 1999;13:F23-F8.
15. Martinez-Picado J., Savana A.V., Sutton L., et al. Replicative fitness of protease inhibitor-resistance mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-52.
16. Condra J., Holder D., Schleif W., et al. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. Antiviral Ther 1999;4 (Suppl. 1): 44.
17. Atkinson B., Isaacson J., Knowles M., et al. Correlation between HIV genotypic resistance and virologic response in patient receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis 2000;182:420-7.
18. Saah A., Haas D.W., Rhodes R., et al. Virologic response to indinavir (IDV), efavirenz (EFV) and adefovir (ADV) among patients failing nelfinavir (NFV). In: Program and abstracts of the WIII International Conference on AIDS; July 9-14,2000; Durban, South Africa. Abstract WePeB4169.
19. International AIDS society-USA resistance Mutations Project Panel. Drug resistance mutations in HIV-1. http://wwwiasusa.org. Accessed October 30, 2003.